NUVL
Price
$107.06
Change
+$2.82 (+2.71%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
7.78B
104 days until earnings call
Intraday BUY SELL Signals
RARE
Price
$31.86
Change
-$0.97 (-2.95%)
Updated
Nov 19 closing price
Capitalization
3.07B
84 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NUVL vs RARE

Header iconNUVL vs RARE Comparison
Open Charts NUVL vs RAREBanner chart's image
Nuvalent
Price$107.06
Change+$2.82 (+2.71%)
Volume$30.16K
Capitalization7.78B
Ultragenyx Pharmaceutical
Price$31.86
Change-$0.97 (-2.95%)
Volume$1.07M
Capitalization3.07B
NUVL vs RARE Comparison Chart in %
NUVL
Daily Signal:
Gain/Loss:
RARE
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
NUVL vs. RARE commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVL is a Hold and RARE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (NUVL: $107.06 vs. RARE: $31.85)
Brand notoriety: NUVL and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVL: 385% vs. RARE: 70%
Market capitalization -- NUVL: $7.78B vs. RARE: $3.07B
NUVL [@Biotechnology] is valued at $7.78B. RARE’s [@Biotechnology] market capitalization is $3.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVL’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • NUVL’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, NUVL is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVL’s TA Score shows that 4 TA indicator(s) are bullish while RARE’s TA Score has 4 bullish TA indicator(s).

  • NUVL’s TA Score: 4 bullish, 4 bearish.
  • RARE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than RARE.

Price Growth

NUVL (@Biotechnology) experienced а +10.34% price change this week, while RARE (@Biotechnology) price change was -5.01% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

NUVL is expected to report earnings on Mar 04, 2026.

RARE is expected to report earnings on Feb 12, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($7.78B) has a higher market cap than RARE($3.07B). NUVL YTD gains are higher at: 36.765 vs. RARE (-24.293). NUVL has higher annual earnings (EBITDA): -398.38M vs. RARE (-435.33M). NUVL has more cash in the bank: 943M vs. RARE (477M). RARE has higher revenues than NUVL: RARE (610M) vs NUVL (0).
NUVLRARENUVL / RARE
Capitalization7.78B3.07B253%
EBITDA-398.38M-435.33M92%
Gain YTD36.765-24.293-151%
P/E RatioN/AN/A-
Revenue0610M-
Total Cash943M477M198%
Total DebtN/A36.3M-
FUNDAMENTALS RATINGS
RARE: Fundamental Ratings
RARE
OUTLOOK RATING
1..100
56
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
58
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NUVLRARE
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 1 day ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 1 day ago
73%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 8 days ago
78%
Declines
ODDS (%)
Bearish Trend 10 days ago
78%
Bearish Trend 13 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 1 day ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
NUVL
Daily Signal:
Gain/Loss:
RARE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CWMFX65.730.22
+0.34%
American Funds Washington Mutual 529F1
RMQHX667.81N/A
N/A
Rydex Monthly Rbl NASDAQ-100® 2x Strt H
NSIDX14.84N/A
N/A
Northern Small Cap Index
FEIQX35.07N/A
N/A
Franklin Equity Income R6
TIVFX20.28-0.07
-0.34%
American Beacon IMC Int Small Cap Inv

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with RVMD. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+2.71%
RVMD - NUVL
61%
Loosely correlated
-0.04%
XNCR - NUVL
60%
Loosely correlated
-1.62%
IDYA - NUVL
59%
Loosely correlated
-1.72%
XENE - NUVL
59%
Loosely correlated
+0.15%
CGON - NUVL
58%
Loosely correlated
+0.16%
More